GSK
For UK Healthcare Professionals
Articles on other parts of this website may contain promotional information

The Asthma and COPD Audit and Review Toolkit: NHS user perspectives


  • Reading time

    8 min read

  • Rating

    3
    0
  • Your expert

    Expert Placeholder
    Simon Thomas
    Honorary Fellow of the School of Pharmacy & Bioengineering, Keele University and a Director at Prescribing Decision Support

As a follow up to ‘Need help to identify your ‘at risk’ respiratory patients?’ find out from Bharat Patel (Clinical Pharmacist, Rushall Medical Centre, CPPE Clinical Mentor, IMPACT Educational Programme Manager/ Visiting Lecturer Keele University, MPPN Chair) and Jaz Dhillon (Lead Clinical Pharmacist Umbrella Medical Group, Clinical Mentor for Cannock Network, RPSGB Faculty member, Visiting Lecturer Keele University, MPPN Committee) how they’ve used the toolkit in their practice.

"I think the big difference is it is a systematic approach to identifying high risk patients, and by identifying those high risk patients we can devote our resources better"

Placeholder

"The toolkit has been really useful in the last few months, it was minutes in terms of importing searches and identifying those at risk patients"

As a reminder, the free to access and use toolkit, has been designed to support the implementation of many of the National Review of Asthma Deaths and National COPD Audit Programme recommendations and to simplify the search and identification process - GSK sponsored the Asthma and COPD Audit and Review Toolkit.  GSK was involved in scoping for the Toolkit and has reviewed the Toolkit for compliance with the ABPI Code. The toolkit was developed as part of a partnership between the Midlands Practice Pharmacy Network and Prescribing Decision Support Ltd at the Centre for Medicines Optimisation, Keele University.

The Asthma and COPD Audit and Review Toolkit  is a free, downloadable resource which incorporates SNOMED CT coding and consists of eight distinct protocol alerts and a consolidated search report.  All search queries and reports incorporate many of the risk factors identified by the National Review of Asthma Deaths and National COPD Audit Programme.  In turn, this will help practitioners identify and prioritise both asthma and COPD patients for review who may be at risk of exacerbations, unplanned admissions and/or displaying signs of poor disease control. 

The Asthma and COPD Audit and Review Toolkit is now available on EMIS and SystmOne. 

"It has sped up the reviews and increased the number of patients we are getting through"

NP-GB-RS-WCNT-200041 November 2020

Rate this article

  • Reading time

    8 min read

  • Rating

    3
    0
  • Your expert

    Expert Placeholder
    Simon Thomas
    Honorary Fellow of the School of Pharmacy & Bioengineering, Keele University and a Director at Prescribing Decision Support